Executive Intelligence

James Field

Founder

James Field is listed as a founder of LabGenius based in United Kingdom on Brel Digital’s verified company intelligence record.

In this profile

Quick Facts

  • Role Founder
  • Company LabGenius
  • Country United Kingdom
  • Industry AI in Healthcare
  • Founded 2012
  • Known For LabGenius represents closed-loop biotech — its EVA platform generates antibody design hypotheses, tests them in automated…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

James Field appears in Brel Digital’s verified company_founders attribution for LabGenius based in United Kingdom in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified LabGenius profile): London antibody discovery company combining EVA machine-learning platform with robotic experimentation for multispecific therapeutic antibodies Why the company matters (verified company field): LabGenius represents closed-loop biotech — its EVA platform generates antibody design hypotheses, tests them in automated wet labs, and feeds results back into models, producing lead assets like LGTX-101 Nectin-4 x CD3 T-cell engager with >70,000-fold killing selectivity cited on its pipeline page. Official company website on file: https://labgeniustx.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2012 Company founded

    LabGenius was founded in 2012 per the company profile source on file.

    Source
  2. 2012 Development

    2012: LabGenius founded in London by James Field during PhD studies at Imperial College London.

    Source
  3. 2025 Development

    2025: ESMO IO poster for Nectin-4 x CD3 T-cell engager; expanded Sanofi collaboration on antibody optimisation.

    Source
  4. 2026 Development

    June 18, 2026: LabGenius announced LG Chem research collaboration for AI/ML-designed tumour-targeting antibody.

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

James Field appears in Brel Digital’s verified company_founders attribution for LabGenius based in United Kingdom in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified LabGenius profile): London antibody discovery company combining EVA machine-learning platform with robotic experimentation for multispecific therapeutic antibodies

Why the company matters (verified company field): LabGenius represents closed-loop biotech — its EVA platform generates antibody design hypotheses, tests them in automated wet labs, and feeds results back into models, producing lead assets like LGTX-101 Nectin-4 x CD3 T-cell engager with >70,000-fold killing selectivity cited on its pipeline page.

Official company website on file: https://labgeniustx.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

The AI Brief

Founder and company intelligence, weekly.

Subscribe